Biotech firm ImmunoScape on Tuesday announced USD11m under global equity financing round led by US-based venture firm Anzu Partners and joined by University of Tokyo Edge Capital (UTEC) in Japan and NPR Holdings in Indonesia.

ImmunoScape's immune profiling platform, which provides deep insights into the T-cells of the human immune system, is already intensely engaged in COVID-19 related programmes in three continents. The company has established collaborations with several vaccine development companies, including the San Diego-based Arcturus, which is running clinical trials in Singapore.

In global collaborations with Massachusetts General Hospital, University of Parma (Italy) and Duke-NUS, ImmunoScape is evaluating COVID-19 patients and recovered individuals. It is building a large data set on human T-cell response to COVID-19 to develop new therapies and better vaccines with its partners. ImmunoScape's technology is based on work from Stanford University and A*STAR of Singapore, disclosed ImmunoScape's co-founder and COO Dr Alessandra Nardin.